Experience of the use of ixabepilone in polychemotherapy regimens for disseminated triple-negative breast cancer
- Authors: Glazkova E.V1, Frolova M.A1, Menshikov S.F1, Stenina M.B1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Issue: Vol 26, No 12 (2019)
- Pages: 15-18
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312335
- DOI: https://doi.org/10.18565/pharmateca.2019.12.15-18
- ID: 312335
Cite item
Open Access
Access granted
Abstract
Therapy of disseminated triple-negative breast cancer (BC) remains an acute problem when choosing a treatment strategy. To date, there is no targeted therapy for this BC subtype that can significantly increase life expectancy. The main treatment for triple-negative BC is chemotherapy, whose reserves are limited due to the rapid development of drug resistance. Unfortunately, the efficacy of antitumor drugs shown in clinical trials is not always translated into clinical practice with comparable results of efficacy and safety. Ixabepilone, a representative of epothilones, has been shown to be effective in the treatment of triple-negative breast cancer resistant to taxanes and anthracyclines. We present our experience in the use of ixabepilone in polychemotherapy regimens for disseminated triple-negative BC.
Full Text
About the authors
E. V Glazkova
N.N. Blokhin National Medical Research Center of Oncology
Email: mdglazkova@gmail.com
23, Kashirskoye Highway, Moscow 115478, Russian Federation
M. A Frolova
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
S. F Menshikov
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
M. B Stenina
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
References
- Kassam F., Enright K., Dent R., et ai. Survival outcomes for patients with metastatic triplenegative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer. 2009;9(1):29-33. Doi: 10.3816/ CBC.2009.n.005.
- Perez E.A., Lerzo G., Pivot X., et al. Efficacy and safety of ixabepilone (BMS-247550) in Phase ii Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane And Capecitabine. JCO. 2007;25(23): 3407-14. doi: 10.1200/JCO.2006.09. 3849.
- Thomas E.S., Gomez H.L., Li R.K., et al. ixabepilone Plus Capecitabine for Metaststic Breast Cancer Progressing After Anthracycline and Taxane Treatment. JCO. 2007;25(33):5210-17. doi: 10.1200/JCO.2007.12.6557.
- Perez E.A., Patel T, Moreno-Aspitia A. Efficacy of ixabepilone in ER/PR/HER2-negative (triplenegative) breast cancer. Breast Cancer Res Treat. 2010;121(2):261-71.
- Valero V, Bosserman L.D., Yardley D.A., et al. Maintenance of clinical efficacy following dose reduction of ixabepilone plus capecitabine (Cape) in patients (pts) with anthracycline (A) and taxane (T) pretreated (pretx) metastatic breast cancer (MBC): a retrospective analysis of pooled data from two phase iii clinical studies (046/048). J Clin Oncol. 2010;28(suppl):abstract: 1051.
Supplementary files
